Hims & Hers Health Inc. HIMS shares are climbing after Barclays reiterated its bullish stance and lifted its price target ...
Zacks Investment Research on MSN
Hims & Hers Health, Inc. (HIMS) is a trending stock: Facts to know before betting on it
Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
2d
HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership
Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.
2d
HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
Analysts and investors have turned their attention to a key regulatory meeting on peptides, a decision expected to trigger ...
Hims & Hers has made clear its interest in the peptides. It owns a peptide manufacturer and said it “sees meaningful ...
Hims & Hers rallied by 12.49 percent on Monday to finish at $30.17 apiece, as investors cheered rosy growth prospects for the ...
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2024 ...
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial ...
Short interest in Hims & Hers Health (HIMS) has spiked as shares of the telehealth platform plunged after Novo Nordisk (NVO) sued the company, challenging its now-withdrawn copycat version of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results